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Long‑term effects of medical 
management on growth 
and weight in individuals with urea 
cycle disorders
Roland Posset1,49, Sven F. Garbade1,49, Florian Gleich1, Andrea L. Gropman2, 
Pascale de Lonlay3, Georg F. Hoffmann1, Angeles Garcia‑Cazorla4, Sandesh C. S. Nagamani5, 
Matthias R. Baumgartner6, Andreas Schulze7, Dries Dobbelaere8, Marc Yudkoff9, 
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Low protein diet and sodium or glycerol phenylbutyrate, two pillars of recommended long‑term 
therapy of individuals with urea cycle disorders (UCDs), involve the risk of iatrogenic growth failure. 
Limited evidence‑based studies hamper our knowledge on the long‑term effects of the proposed 
medical management in individuals with UCDs. We studied the impact of medical management on 
growth and weight development in 307 individuals longitudinally followed by the Urea Cycle Disorders 
Consortium (UCDC) and the European registry and network for Intoxication type Metabolic Diseases 
(E‑IMD). Intrauterine growth of all investigated UCDs and postnatal linear growth of asymptomatic 
individuals remained unaffected. Symptomatic individuals were at risk of progressive growth 
retardation independent from the underlying disease and the degree of natural protein restriction. 
Growth impairment was determined by disease severity and associated with reduced or borderline 
plasma branched‑chain amino acid (BCAA) concentrations. Liver transplantation appeared to have 
a beneficial effect on growth. Weight development remained unaffected both in asymptomatic and 
symptomatic individuals. Progressive growth impairment depends on disease severity and plasma 
BCAA concentrations, but cannot be predicted by the amount of natural protein intake alone. Future 
clinical trials are necessary to evaluate whether supplementation with BCAAs might improve growth 
in UCDs.
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ASL-D  Argininosuccinate lyase deficiency
ASS1-D  Argininosuccinate synthetase 1 deficiency
BCAA(s)  Branched-chain amino acid(s)
BCAT(s)  BCAA transaminase(s)
BMI  Body mass index
BZA  Sodium benzoate
EAA(s)  Essential amino acid(s)
E-IMD  European registry and network for Intoxication type Metabolic Diseases
EO  Early onset (≤ 28 days)
fOTC-D  Female ornithine transcarbamylase deficiency
IQR  Interquartile range
LO  Late onset (> 28 days)
LTx  Liver transplantation
mOTC-D  Male ornithine transcarbamylase deficiency
NH4
+
max  Peak plasma ammonium concentration
PBA  (Sodium or glycerol) phenylbutyrate
SDS  Standard deviation score
UCDC  Urea Cycle Disorders Consortium
UCD(s)  Urea cycle disorder(s)
Urea cycle disorders (UCDs) are rare inherited metabolic diseases, consisting of 5 enzymopathies, 2 transport-
ers and 2 associated cofactor-producing enzymes, with an estimated overall prevalence of 1 in 35,000 to 52,000 
 newborns1. The phenotypic spectrum is wide ranging from severe life-threatening hyperammonemic decompen-
sations within the first 28 days of life (EO, early onset) to mild or moderate chronic hyperammonemic conditions 
reflected by a heterogeneous clinical spectrum such as lethargy, headache, hepatological, gastrointenstinal and 
neurological or psychiatric symptoms any time after the neonatal period (LO, late onset)2–4. Long-term dietary 
management is challenging and consists of a low protein diet with or without supplementation of essential amino 
acids (EAAs), vitamins, trace elements and/or single amino acids, while pharmacological long-term treatment 
with nitrogen scavengers, i.e. sodium benzoate (BZA) and sodium or glycerol phenylbutyrate (PBA), aims at 
improving the urinary excretion of waste nitrogen via alternative pathways to reduce the frequency and severity 
of hyperammonemic episodes and hence improve survival and clinical outcomes of affected  individuals2, 5. How-
ever, a protein restricted diet, defined by a natural protein intake below 100% of the World Health Organization 
(WHO) safe values  recommendations6, as well as depletion of branched-chain amino acids (BCAAs), the latter 
aggravated by the administration of  PBA7, are thought to impair growth and weight development. Recently, 
survey-based studies from the UK and Europe found that dietary treatment practices vary widely between 
different countries, particularly with regard to daily protein prescriptions in early childhood, use of EAAs and 
BCAA supplementation, and nutritional support with vitamins, trace elements, minerals and essential fatty acids. 
Moreover, clinical trials investigating dietary treatment outcomes between different severity-adjusted UCD sub-
groups with regard to clinical endpoints, such as growth or metabolic stability, are still  lacking8–10. Thus, current 
recommendations for dietary and pharmacological long-term management remain inconclusive due to missing 
longitudinal studies evaluating the (adverse) effects of current treatment  principles2,5,8,9.
Based on a combined and comparative data analysis approach between large international multicenter registry 
studies from North America [Urea Cycle Disorders Consortium (UCDC; https ://www.rared iseas esnet work.org/
cms/ucdc)] and Europe [European registry and network for Intoxication type Metabolic Disease (E-IMD; https 
://www.eimd-regis try.org/)], a new strategy for clinical outcome research in the field of rare diseases became 
lately  available11. This enabled us to evaluate the impact of long-term management on the cognitive outcome 
of individuals with UCDs, providing further evidence for future  recommendations12. Due to the low clinical 
evidence with regard to the long-term (adverse) effects of medical treatment, we studied longitudinal data from 
the UCDC and E-IMD databases to address this shortcoming after two decades of systematic data collection.
To this end, we investigated whether individuals with UCDs suffer from intrauterine or postnatal weight and 
growth retardation, and whether medical management—as currently performed in symptomatic individuals 
with UCDs in North America and Europe—is safe or leads to an impaired development with regard to anthro-
pometrical endpoints.
Results
Anthropometrical parameters at birth are within normal range. Overall, 205 individuals with 
UCDs [male ornithine transcarbamylase deficiency (mOTC-D): n = 54, 26.4%; female OTC-D (fOTC-D): n = 39, 
19.0%; argininosuccinate synthetase 1 deficiency (ASS1-D): n = 64, 31.2%; argininosuccinate lyase deficiency 
(ASL-D): n = 48, 23.4%] have a mean z-score within the normal range for birth weight, length and head circum-
ference [mean z-score (birth weight): − 0.24; mean z-score (birth length): 0.14; mean z-score (birth head cir-
cumference): − 0.13] (Fig. 1A–C). Neither disease (mOTC-D, fOTC-D, ASS1-D, ASL-D) nor sex (male, female) 
showed a specific impact on birth weight (disease: p = 0.18, sex: p = 0.15; ANOVA), birth length (disease: p = 0.30, 
sex: p = 0.57; ANOVA), or birth head circumference (disease: p = 0.74, sex: p = 0.09; ANOVA).
Asymptomatic individuals have a normal postnatal growth and weight development. Next, 
we studied the postnatal anthropometrical development of asymptomatic and untreated individuals with UCDs. 
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Overall 11 individuals (mOTC-D: n = 2, 18.2%; fOTC-D: n = 3, 27.3%; ASS1-D: n = 4, 36.3%; ASL-D: n = 2, 
18.2%) with a mean individual observation period of 2.95 years (min: 1.59 years; max: 4.54 years) were inves-
tigated. Mean age at first visit was 1.56 years (min: 0.01 years; max: 8.71 years) and mean age at last visit cor-
responded to 4.51 years (min: 1.96 years; max: 12.27 years), reflecting a preschool population of UCDs. Neither 
disease nor age showed an impact on postnatal weight development (disease: p = 0.33, age: p = 0.27; ANOVA) 
and linear growth (disease: p = 0.72, age: p = 0.16; ANOVA) within the observation period (Fig. 2A,B), highlight-
ing that asymptomatic individuals with UCDs have a normal postnatal anthropometrical development.
Symptomatic individuals have a risk of postnatal growth retardation. To assess whether symp-
tomatic individuals had a risk of postnatal weight and growth retardation, we evaluated 130 symptomatic indi-
viduals (mOTC-D: n = 33, 25.4%; fOTC-D: n = 42, 32.3%; ASS1-D: n = 25, 19.2%; ASL-D: n = 30, 23.1%) receiv-
ing conservative management during a mean individual observation period of 4.81 years (min: 1.00 years; max: 
12.44 years). Overall, the observation period spanned a time frame within prepubertal childhood from mean 
age at first visit of 6.33 years (min: 0.03 years; max: 15.52 years) to mean age at last visit of 11.14 years (min: 
1.27 years; max: 17.99 years). Since early disease onset was associated with higher disease  severity10, we inves-
tigated whether specific diseases were associated with higher initial peak plasma ammonium concentrations 
 (NH4
+
max) in our study population. Interaction between disease onset (EO vs. LO) and a specific disease (mOTC-
D, fOTC-D, ASS1-D, ASL-D) was not significant (p = 0.86; LME ANOVA). Furthermore, neither disease onset 
(p = 0.77; LME ANOVA), nor a specific disease (p = 0.71; LME ANOVA) or age (p = 0.41; LME ANOVA) had 
a measurable impact on weight gain during the observation period, demonstrating that current conservative 
management does not impair weight development of symptomatic individuals with UCDs (Fig. 3A). In contrast, 
symptomatic individuals suffered from postnatal growth retardation. This was not associated with a specific 
UCD (p = 0.45; LME ANOVA), while disease onset (p = 0.03; LME ANOVA), age (p < 0.001; LME ANOVA), 
Figure 1.  Intrauterine development of 205 individuals with UCDs is unaffected. Z-scores of weight (A), length 
(B), and head circumference (C) of 205 individuals with UCDs at birth. Mean z-scores for weight (z-score: 
− 0.24), length (z-score: 0.14) and head circumference (z-score: − 0.13) are overall within the normal range. 
Various diseases do not differ with regard to weight (p = 0.20; ANOVA), length (p = 0.26; ANOVA), and head 
circumference (p = 0.11; ANOVA). Data are shown as median (black line) and mean (triangle), length of the 
box corresponds to interquartile range (IQR), upper and lower whiskers correspond to max. 1.5 × IQR, each 
point represents an outlier. Descriptive characteristics are presented separately in Supplementary Table S1. 
ASL-D, argininosuccinate lyase deficiency; ASS1-D, argininosuccinate synthetase 1 deficiency; fOTC-D, female 
ornithine transcarbamylase deficiency; mOTC-D, male ornithine transcarbamylase deficiency.
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and interaction between disease onset and age (p < 0.001; LME ANOVA) had a significant impact on linear 
growth indicating that particularly EO patients of any UCD studied suffered from postnatal growth retardation 
(Fig. 3B). Accordingly, body mass index (BMI) of affected individuals increased over time for the EO but not LO 
group as indicated by a significant interaction between disease onset and age (p = 0.02; LME ANOVA; Fig. 3C).
Postnatal growth retardation in symptomatic individuals with UCDs is not associated with a 
protein restricted diet. To evaluate whether the observed postnatal growth retardation in symptomatic indi-
viduals was due to the protein restricted diet or the caloric intake as part of the conservative management, we stud-
ied 46 severity-adjusted UCD individuals (mOTC-D: n = 9, 19.6%; fOTC-D: n = 11, 23.9%; ASS1-D: n = 11, 23.9%; 
ASL-D: n = 15, 32.6%) with sufficient information on biochemical and therapy-related longitudinal data, compris-
ing a mean individual observation period of 3.13 years (min: 1.01 years; max: 9.94 years) within the preschool age. 
Overall, half of the patients received a protein restricted diet (mOTC-D: n = 3, 13.0%; fOTC-D: n = 5, 21.7%; ASS1-
D: n = 4, 17.5%; ASL-D: n = 11, 47.8%), while 50% of patients received no protein restricted diet (mOTC-D: n = 6, 
26.1%; fOTC-D: n = 6, 26.1%; ASS1-D: n = 7, 30.4%; ASL-D: n = 4, 17.4%). Individuals with and without a protein 
restricted diet did not differ with regard to their initial  NH4
+
max (p = 0.20; t-test). In addition, the degree of protein 
restriction was not disease-dependent in individuals receiving a protein restricted diet (p = 0.28; LME ANOVA), 
but showed an overlapping mean natural protein intake ranging from 62.95% to 77.45% WHO in mOTC-D, fOTC-
D, ASS1-D, and ASL-D (Fig. 4A). In analogy, a protein restricted diet had no impact on weight gain. Neither age 
(p = 0.48; LME ANOVA) nor application of a protein restricted diet (p = 0.43; LME ANOVA) or interaction of both 
(p = 0.98; LME ANOVA) affected weight development (Fig. 4B). Regardless of this, symptomatic individuals receiv-
ing conservative medical management developed a progressive growth retardation (p = 0.008; LME ANOVA). 
However, this was not explained by the use of a protein restricted diet (p = 0.61; LME ANOVA), showing that both 
symptomatic individuals with or without a protein restricted diet (p = 0.27; LME ANOVA) experienced postnatal 
growth retardation (Fig. 4C). Based on 39.1% (n = 18/46) of individuals in this sample with sufficient data density, 
mean caloric intake does not appear to be associated with growth retardation (p = 0.32; LME ANOVA).
Symptomatic UCDs have reduced to low normal plasma BCAA concentrations. Since growth 
retardation was independent from the use of a protein restricted diet, we wondered whether BCAA concentra-
tions (L-valine, L-leucine, L-isoleucine) might contribute to impaired growth in symptomatic individuals with 
or without a protein restricted diet. Therefore, we investigated the weighted arithmetic mean values of plasma 
BCAAs along with the weighted arithmetic mean dosage of EAA supplements during the individual observa-
tion periods in both individuals with and without a protein restricted diet. Although individuals with a protein 
restricted diet received a higher weighted arithmetic mean dosage of EAA supplements (p = 0.03; t-test), concen-
trations of L-valine (p = 0.25; t-test), L-leucine (p = 0.06; t-test), and L-isoleucine (p = 0.24; t-test) did not differ 
between groups (Table 1), but were found to be reduced or at the lower end of the reference  range13. Weighted 
arithmetic mean values of plasma L-arginine did not differ between both groups (p = 0.78; t-test), but were, in 
contrast to plasma BCAA concentrations, within the normal or upper end of the reference  range13. Moreover, 
application of nitrogen scavengers (mono- or biscavenger therapy) showed a similar distribution between groups.
Figure 2.  Postnatal weight development and linear growth of 11 asymptomatic UCDs is normal. Preschool 
children were observed during a period of approximately 3 years and both weight (A) and height (B) did 
not differ between the first [mean z-score (weight): 0.09; mean z-score (height): 0.02] and last [mean z-score 
(weight): 0.65; mean z-score (height): 0.62] observation (each p > 0.05; t-test). Moreover, weight and height 
were within the normal range. Data are shown as median (black line) and mean (triangle), length of the box 
corresponds to IQR, upper and lower whiskers correspond to max. 1.5 × IQR. Descriptive characteristics are 
presented separately in Supplementary Table S1.
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Liver transplantation rescues postnatal growth retardation in symptomatic UCDs. To investi-
gate whether LTx might exert a positive effect on growth and weight in severely affected individuals, we analyzed 
both endpoints of liver-transplanted individuals at three different time points, i.e. at first observation (first time 
point), at last observation prior to LTx (second time point), and at last observation after LTx (third time point). 
Overall, 19 individuals (mOTC-D: n = 7, 36.8%; ASS1-D: n = 6, 31.6%; ASL-D: n = 6, 31.6%) receiving LTx at a 
mean age of 2.15 years (min: 0.42 years; max: 7.76 years) were included into this analysis. Disease severity, as 
mirrored by initial  NH4
+
max, did not differ between different diseases (p = 0.60; LME ANOVA). In those 19 trans-
planted individuals, the mean observation time of conservative management (time between first and second 
time point) was 1.91 years, the mean observation time after liver transplantation (time between age at transplan-
tation and third time point) was 4.74 years. In analogy to milder affected individuals who do not undergo LTx, 
liver-transplanted individuals showed normal weight development (mean z-score at first observation: − 0.27, 
mean z-score at last observation prior to LTx: − 0.02, mean z-score at last observation after LTx: 0.05, p = 0.48; 
LME ANOVA) (Fig. 5A). In contrast, age showed an effect on linear growth (p < 0.001; LME ANOVA), sug-
gesting that during conservative management patients develop a postnatal growth retardation (mean z-score at 
first observation: 0.53, mean z-score at last observation prior to LTx: − 0.75, p < 0.001; contrast t-test). After LTx 
however, linear growth of individuals stabilized along a constant z-score (mean z-score at last observation prior 
Figure 3.  Symptomatic individuals (n = 130) have normal weight development but abnormal linear growth. 
Prepubertal children were observed during a period of approximately 5 years. Weight (A) was not affected 
neither by age (p = 0.41; LME ANOVA), nor by disease onset (p = 0.77; LME ANOVA) or specific diseases 
(p = 0.71; LME ANOVA). β-Coefficients did not differ between EO (β = − 0.01) and LO (β = 0.02; p = 0.23, LME) 
individuals. Height (B) however, was affected by age (p < 0.001; LME ANOVA), disease onset (p = 0.03; LME 
ANOVA) and interaction of both (p < 0.001; LME ANOVA), suggesting that disease severity—as reflected by 
EO individuals—is associated with impaired growth over time. In line, β-coefficients differed between EO 
(β = − 0.11) and LO (β = − 0.02; p < 0.001, LME) individuals. Accordingly, BMI (C) was determined by age 
(p < 0.001; LME ANOVA) and interaction between age and disease onset (p = 0.02; LME ANOVA), indicating 
that BMI increases with age for the EO but not the LO group. Gray lines are fitted weight, height, and BMI 
values from the LME model; the gray shaded area corresponds to 95% confidence interval. Descriptive 
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to LTx: − 0.75, mean z-score at last observation after LTx: − 0.17, p = 0.13; contrast t-test) (Fig. 5B). Interestingly, 
liver transplantation led to the elevation of all plasma BCAAs concentrations from reduced or low normal values 
before LTx to values well within the normal range after LTx [L-valine (p = 0.001; t-test), L-leucine (p = 0.048; 
t-test), L-isoleucine (p = 0.001; t-test); Table 1].
Discussion
This study aimed at characterizing growth and weight gain in individuals with UCDs and elucidating risk factors 
for potentially impaired anthropometrical development. The study revealed five major results: (1) Intrauterine 
development in all investigated UCDs and postnatal linear growth of asymptomatic and untreated individuals 
were normal. (2) Symptomatic individuals were at risk of developing progressive growth impairment regardless 
of the underlying UCD or degree of natural protein intake. (3) Growth impairment was determined by disease 
severity and associated with reduced or low normal plasma BCAA concentrations. (4) LTx appeared to have a 
beneficial effect on growth. (5) Weight development was normal in both asymptomatic and symptomatic indi-
viduals with UCDs, regardless of the medical management.
Intrauterine growth of the investigated study sample was unaffected as indicated by anthropometrical param-
eters at birth which were within the normal range, thereby confirming previous data from a European cohort 
Figure 4.  Impaired growth is not associated with the use of protein restricted diet as part of medical 
management in 46 symptomatic UCDs. Preschool children receiving a protein restricted diet were similarly 
restricted (p = 0.28; ANOVA) with regard to their mean natural protein intake. Data are shown as median (black 
line) and mean (triangle), length of the box corresponds to IQR, upper and lower whiskers correspond to max. 
1.5 × IQR (A). During an observation period of approximately 3 years individuals with (n = 23) or without 
(n = 23) a protein restricted diet did not differ (each p > 0.05; LME ANOVA) with regard to their normal weight 
development (B) and impaired linear growth (C). β-coefficients did not differ between individuals with or 
without a protein restricted diet neither for weight development (protein restricted diet: β = − 0.01, no protein 
restricted diet: β = − 0.01; p = 0.98, LME; B) nor for linear growth (protein restricted diet: β = − 0.03; no protein 
restricted diet: β = − 0.06; p = 0.28; LME; C). Gray lines are fitted weight and height values from the LME model; 
the gray shaded area corresponds to 95% confidence interval (B, C). Descriptive characteristics are presented 
separately in Supplementary Table S1. ASL-D, argininosuccinate lyase deficiency; ASS1-D, argininosuccinate 
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of individuals with  UCDs3. In asymptomatic UCD individuals not receiving long-term management with low 
protein diet and nitrogen scavengers, linear growth and weight gain remained unaffected until preschool age.
In contrast, symptomatic individuals of any UCD studied receiving conservative management, particularly 
EO individuals, showed progressive growth impairment over time, which is in line with previous  studies14,15, 
highlighting that disease severity rather than the type of UCD is a major determinant of linear growth. Since 
treatment intensity was shown to reflect disease severity and protein restriction has been hypothesized to be 
causally related to growth failure in  UCDs12, we further investigated the impact of current treatment modali-
ties on linear growth, particularly with regard to natural protein intake as underlying cause of potential growth 
retardation. Unexpectedly however, both symptomatic UCD individuals with or without protein restricted diet 
exhibited a progressive growth deficit, indicating that natural protein intake per se does not explain this finding. 
Analogously, caloric intake appeared not to affect neither weight development nor linear growth in the studied 
cohort. However, due to the small study sample for caloric intake, these results should be considered somewhat 
Table 1.  Weighted arithmetic mean values of plasma BCAAs and L-arginine in the study sample. Reference 
ranges were defined according to (20) for children in the age range of 2–10 years and are shown in µmol/l. 
P values were calculated using a two-sided t-test, p values < 0.05 were considered significant, n refers to 
number of patients included in each group. Of note, 65% (n = 15/23) of individuals with a protein restricted 
diet and 59% (n = 13/22) of individuals without a protein restricted diet received (at least temporarily) 
supplementation with L-arginine within the observation period. BCAAs, branched-chain amino acid(s); LTx, 
liver transplantation; n/a, not available.
L-valine L-leucine L-isoleucine L-arginine
Mean, SD; n Mean, SD; n Mean, SD; n Mean, SD; n
Reference range 133–273 64–164 31–83 38–98
Conservative management
Protein restricted diet 145, 54; 23 68, 25; 23 38, 16; 23 73, 33, 23
No protein restricted diet 166, 72; 22 92, 45; 22 45, 23; 22 74, 32, 22
p value 0.25 0.06 0.24 0.78
Liver transplantation
Prior to LTx 144, 58; 18 86, 63; 18 40, 23; 18 n/a
After LTx 224, 70; 15 123, 32; 15 67, 21; 16 n/a
p value 0.001 0.048 0.001 n/a
Figure 5.  Liver transplantation appears to have a beneficial effect on growth of 19 individuals with UCDs. 
Individuals with UCDs (n = 19) have normal weight gain (A) over time pre- and post-transplantation (p = 0.48; 
LME ANOVA), but suffer from impaired growth (B) prior to transplantation [mean z-score at first observation: 
0.53, mean z-sore at last observation prior to LTx: − 0.75; p < 0.001; contrast t-test). However, growth retardation 
does not further aggravate after transplantation (mean z-score at last observation prior to LTx: − 0.75, mean 
z-score at last observation after LTx: − 0.17; p = 0.13; contrast t-test). Data are shown as median (black line) and 
mean (triangle), length of the box corresponds to IQR, upper and lower whiskers correspond to max. 1.5 × IQR, 
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exploratory. Moreover, although weight development was normal in both asymptomatic and symptomatic indi-
viduals with UCDs, it remains to be elucidated whether the composition of body weight in terms of fat and lean 
mass might be affected by medical management.
Recently, it has been shown that supplementation of L-arginine restored plasma IGF-1 and IGF-BP3 levels in 
seven male individuals with LO OTC-D aged 3–5 years and gradually improved linear  growth16. However, UCD 
individuals in our study cohort exhibited progressive growth failure despite plasma L-arginine levels well within 
the normal range independent from protein restriction or supplementation with EAAs, suggesting alternative 
factors causing reduced linear growth in UCDs.
Intriguingly, UCD individuals in both groups (restricted vs. non-restricted) exhibited similarly reduced 
or low normal plasma BCAA concentrations as indicated by the weighted arithmetic mean values for plasma 
L-valine, L-leucine and L-isoleucine concentrations in our study. Maintaining stable concentrations of essential 
and functional BCAAs is crucial to stimulate  growth17, and deficiencies in the amino acids L-valine, L-leucine 
and L-isoleucine have been shown to be associated with growth failure in  children18. Reduced BCAA concen-
trations are a biochemical hallmark in acute and chronic hyperammonemic conditions. Enhanced consump-
tion of BCAAs via increased propionate oxidation as major compensatory mechanism to prevent bioenergetic 
impairment under acute and chronic hyperammonemic conditions has recently been  elucidated19–25, highlight-
ing the role of the deamination of BCAAs for the generation of succinyl-CoA (deamination of isoleucine and 
valine), which can supply the TCA cycle with important carbon backbones. Consistently, individuals with UCDs 
exhibited decreased plasma BCAA concentrations correlating with  hyperammonemia26. Moreover, L-isoleucine 
and L-valine have been shown to be the only amino acids with significant cerebral uptake in patients with ful-
minant hepatic  failure27, and cerebral BCAA transaminases (BCATs) are stimulated under hyperammonemic 
conditions, thereby enhancing the consumption of L-isoleucine and L-valine for anaplerotic reactions as well as 
transamination processes for the generation of L-glutamate and L-glutamine (consumption of L-valine, L-leucine 
and L-isoleucine) via activities of BCAT1 and BCAT2,  respectively28. Notably, male mice hemizygous for the 
 OTCspf-ash mutation, which is characterized by chronically elevated  NH4
+ concentrations without spontaneously 
occurring acute hyperammonemic decompensations, exhibited growth failure with significantly reduced body 
height under regular diet when compared to their wildtype littermates at 4–6  months29,30, indicating that growth 
failure in UCD might be causatively linked to the chronically elevated  NH4
+ concentrations and subsequent 
depletion of BCAAs due to enhanced propionate oxidation. Moreover, sodium or glycerol PBA prevents the 
phosphorylation of the E1α subunit of the branched-chain α-keto acid dehydrogenase complex (BCKDHc) 
via inhibition of the BCKDHc kinase, resulting in activation of BCKDHc and increased breakdown of BCAA, 
resulting in synergistic reduction of plasma BCAA  concentrations7.
In line, height z-scores in UCD patients were positively associated with patient’s plasma L-leucine (CPS1-D, 
mOTC-D and HHH-syndrome) and L-valine (ASS1-D and ASL-D)  concentrations14, clearly supporting our 
findings. However, while the latter observation was based on a cross-sectional analysis, our results further sub-
stantiate the relevance of the identified association between BCAA depletion and growth failure by providing 
longitudinal data in UCDs. Of note, plasma BCAA concentrations were within the lower normal range or reduced 
in UCD individuals in our study, independent from the administration of EAA supplements, which has already 
been reported by Molema et al.14, indicating that the current clinical practice of prescribing EAA or BCAA sup-
plements is not sufficiently compensating for BCAA depletion in UCD individuals. Since LTx appeared to be 
beneficial for the cognitive outcome in UCD individuals in a cross-sectional  analysis12,14, we further investigated 
the impact of LTx on linear growth. Intriguingly, UCD individuals who exhibited growth impairment with 
decreasing height z-scores prior to LTx, did show a stable linear growth within a mean individual observation 
period of 4 years after LTx, suggesting that LTx might also prove beneficial for linear growth in UCDs. Further 
systematic prospective long-term follow-up investigation and increased number of analyzed individuals will be 
crucial to reliably determine the effect of LTx on linear growth. However, our findings are not unexpected, since 
LTx is an effective measure to correct the enzymatic defect thereby preventing further hyperammonemic episodes 
and subsequent consumption of BCAAs induced by elevated  NH4
+ concentrations as well as the necessity of 
protein restriction and long-term nitrogen scavenger therapy. Of note, this is substantiated by our finding that 
plasma BCAA concentrations normalized after LTx in the study sample investigated.
This analysis has several inherent limitations. While both, the E-IMD and UCDC registry contain detailed 
information on dietary prescriptions, they do not verify and describe the actual daily intake by a participating 
UCD individual or adequately control for patient compliance. Furthermore, there was no information on the 
quality of natural protein consumed. Practice of dietary management may vary considerably between different 
study centers of both consortia. Moreover, the first data entry used for different analyses might not reflect the 
exact time period between diagnosis and implementation of a specific treatment, which might have introduced 
some noise into the data due to inadequate or varying treatment modalities prior to first assessment. Next, bio-
chemical values (plasma concentrations of  NH4
+, BCAAs and L-arginine) were not assessed in a central labora-
tory using a standardized protocol and therefore reference values differ slightly between participating study sites. 
There was no assessment neither of the quality of the preanalytical process nor the correctness of measurements 
and potential differences between contributing laboratories. Due to small sample sizes, a comparative analysis 
regarding the effect of a specific nitrogen scavenger (BZA vs. PBA) on plasma BCAA concentrations could not 
be performed and thus remains subject to future studies. Study visits in both registries usually are several months 
apart, therefore it has to be implied that the status recorded at any given point is representative for the preceding 
interval. Given the observational nature of this international, multicenter registry study, data sets can have miss-
ing values. Thus, the prospective study was performed using solely available data, which is only valid under the 
missing completely at random (MCAR) assumption. No methods of imputation of missing data were applied. 
Further intraindividual long-term follow up studies are needed, to substantiate our findings and to systematically 
assess linear growth in UCD individuals beyond the preschool age.
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Conclusions
Our longitudinal study reveals, that intrauterine development in all investigated UCDs as well as postnatal linear 
growth and weight progress of asymptomatic individuals in the absence of hyperammonemic episodes and/or 
conservative treatment is unaffected. In contrast, symptomatic individuals are at risk of developing progressive 
growth impairment over time independent from the underlying disease and the degree of natural protein restric-
tion. Growth impairment is associated with reduced or borderline plasma BCAA concentrations. Moreover, 
LTx appeared to have a beneficial effect on linear growth. Future prospective clinical trials are indispensable 
to unequivocally prove the pathomechanistic role of BCAA depletion on impaired linear growth and potential 
beneficial effects of adequate EAA supplementation in UCDs.
Materials and methods
Eligibility criteria and overview of the UCDC and E‑IMD databases. In brief, the UCDC database 
is registered in the U.S. National Library of Medicine (https ://clini caltr ials.gov), whereas the E-IMD registry is 
recorded on the German Clinical Trials Register (https ://www.drks.de). Requirements set forth by the ICMJE 
(International Committee of Medical Journal Editors) were met. All procedures were in accordance with the 
ethical standards of the Helsinki Declaration of 1975, as revised in 2013. The E-IMD and UCDC study protocols 
have received approval by the Institutional Review Board of the Medical Faculty of Heidelberg University (Ethik-
kommission der Medizinischen Fakultät Heidelberg, Germany; lead institution for this study, permit S-525/2010 
and S-198/2011) and were also approved by all ethics committees of the participating North-American and 
European study sites. Written informed consent was obtained from all participants prior to inclusion in both 
databases. Both registries use remote data entry via electronic case report forms comprising clinical, biochemical 
and therapy-related data from baseline, scheduled regular follow-up investigations, and unscheduled (emer-
gency) visits to the hospital. A detailed description of the combined and comparative research approach is pro-
vided  separately11.
Cornerstones and strategy for data analysis. Cut-off date for data analysis was February 25, 2019. 
Since the scope of this analysis comprised the effects of dietary long-term management, only data from baseline 
and regular follow-up visits were considered eligible. All subsequent analyses focus on individuals with OTC-D 
(MIM #311250), ASS1-D (MIM #215700), and ASL-D (MIM #207900) forming the study sample for this anal-
ysis, and investigating the majority of individuals with  UCDs3,11,31. Ultra-rare UCDs with a disease-specific 
incidence of equal to or below 1:1,000,00032, such as N-acetylglutamate synthase deficiency, carbamolyphos-
phate synthetase 1 deficiency, carboanhydrase VA deficiency, arginase 1 deficiency, hyperornithinemia-hyper-
ammonemia-homocitrullinuria syndrome, and citrin deficiency are subject to future studies. We analyzed the 
effect of dietary long-term management on the anthropometrical endpoints weight, height and, if available, 
head circumference. Since we showed recently that therapeutic intensity depends on the phenotypic severity 
of individuals with  UCDs12, our study sample (individuals with mOTC-D, fOTC-D, ASS1-D, and ASL-D) was 
severity-adjusted. To this end, individual observation periods were defined for each patient within the study 
sample, reflecting a period of specific therapy intensity, and thus specific phenotypic severity. The regular visit 
prior to therapy escalation or therapy de-escalation corresponded to the last observation timepoint within the 
individuals’ observation periods. Therapy escalation was defined as newly introduced application of mono- or 
combined scavengers, therapy de-escalation was considered as discontinuation of mono- or biscavenger therapy. 
Each individual within the study sample had at least two successive visits with a maximum interval of 18 months. 
The minimum duration of an individual observation period for each individual corresponded to 12 months. 
Visits within the individual observation periods provided information on biochemical values, dietary and phar-
macological management, and anthropometrical endpoints.
European individuals with UCDs were compared to growth charts from the UK, since the ethnical back-
ground of the European UCD sample corresponds well to the  UK3,33, while for North American individuals the 
Center for Disease Control and Prevention growth charts (https ://www.cdc.gov/growt hchar ts/cdc_chart s.htm) 
were used. Z-scores for height, weight, BMI and head circumference were calculated at baseline and each regu-
lar follow-up visit. Preterm infants (< 37th pregnancy week), and z-scores < -3 or > 3 were excluded from data 
analysis due to probably erroneous entries into the databases. Mean natural protein intake (g/kg/d), mean EAA 
intake (g/kg/d), and mean caloric intake (kcal/kg/d) were calculated for the patients’ individual observation 
periods (using time weighted averages based on data from each available visit) and were indicated as percentage 
of WHO safe values recommendations for mean natural protein and mean EAA  intake6, and in percentage of 
Food and Agriculture Organizations of the United Nations (FAO) for mean caloric  intake34. Individuals receiv-
ing a mean natural protein intake below 100% WHO safe values during the observation period were considered 
to have a protein restricted diet. To monitor BCAA levels during the patients’ individual observation periods, 
mean plasma levels for L-valine, L-leucine, L-isoleucine, and L-arginine (all in µmol/l) were calculated, where 
available. Moreover, use of nitrogen scavengers was documented within the individuals’ observation periods. 
Only individuals until the age of 18 years were included into this study.
Inclusion and exclusion criteria. Overall, 307 individuals with UCDs were eligible for data analysis 
(mOTC-D: n = 82, 26.7%; fOTC-D: n = 76, 24.8%; ASS1-D: n = 78, 25.4%; ASL-D: n = 71, 23.1%). Individuals 
belonging to specific UCD subgroups were included in subsequent analysis, defined by distinct inclusion and 
exclusion criteria. Descriptive characteristics of those subgroups are presented in the corresponding results 
section and in Supplementary Table S1. Analysis 1 (“Anthropometrical parameters at birth are within normal 
range”) investigated if individuals with UCD suffered from intrauterine retardation of growth, weight, and head 
circumference (inclusion criteria: birth weight, length and head circumference measured within the first 2 weeks 
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of life). Analysis 2 (“Asymptomatic individuals have a normal postnatal growth and weight development”) evalu-
ated whether asymptomatic and untreated individuals had a normal or impaired postnatal anthropometrical 
development (inclusion criteria: asymptomatic individuals with UCDs; study inclusion within 12 months after 
age at diagnosis; no scavengers and no protein restricted diet within the individuals’ observation periods). Anal-
ysis 3  (“Symptomatic individuals have a risk of postnatal growth retardation”) investigated whether sympto-
matic individuals with UCDs receiving conservative management were at risk of growth and weight retardation 
(inclusion criteria: symptomatic individuals with UCDs, study inclusion within 12 months after age at diagnosis; 
exclusion criteria: asymptomatic individuals with UCDs, individuals receiving a LTx). Analysis 4 (“Postnatal 
growth retardation in symptomatic individuals with UCDs is not associated with a protein restricted diet”) stud-
ied whether symptomatic individuals with a protein restricted diet are at risk of developing impaired growth and 
weight compared to individuals without a protein restricted diet (inclusion criteria: see analysis 3, additionally 
only individuals with sufficient information on biochemical and therapy-related longitudinal data allowing the 
calculation of mean values were included; exclusion criteria: see analysis 3). Analysis 5 (“Liver transplantation 
rescues postnatal growth retardation in symptomatic UCDs”) investigated whether individuals receiving LTx 
suffered from pre- and post-transplant growth and weight retardation [inclusion criteria: individuals receiving a 
LTx with three distinct time points of growth and weight (first time point: first observation; second time point: 
last observation prior to LTx; third time point: last observation after LTx), time lag between 2nd and 3rd time 
point at least 12 months; exclusion criteria: individuals with conservative management].
Data availability. The datasets generated and analyzed during the current study are not publicly available 
due to existing data protection laws. Furthermore, data ownership is retained by the members of the UCDC and 
E-IMD consortia making anonymized data available for specific research purposes. Data availability is subject to 
the consent of both consortia upon request.
Statistical analysis. All statistical analyses were performed using R, a language for statistical computing 
and graphics (https ://www.r-proje ct.org). Multiple regression analyses were used to model a numeric depend-
ent outcome variable with respect to several independent predictor variables. Longitudinal data was modelled 
with a linear mixed effect model (LME) with individuals as random factor. For multiple regression and LME, 
results were displayed with analysis of variance (ANOVA) tables with type two F-tests and post-hoc comparisons 
(contrasts) were carried out with t-tests based on estimated marginal  means35. Two groups were compared with 
Welch two sample t-test, paired data with a paired t-test.
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